Description
SUSD3 Antibody | 8475 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human, Mouse
Homology: N/A
Immunogen: SUSD3 antibody was raised against a 16 amino acid peptide from near the center of human SUSD3.
The immunogen is located within amino acids 120 - 170 of SUSD3.
Research Area: Cell Cycle, Cancer
Tested Application: E, WB, ICC
Application: SUSD3 antibody can be used for the detection of SUSD3 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunocytochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunocytochemistry in mouse samples. All other applications and species not yet tested.
Specificiy: SUSD3 antibody is human and mouse reactive. Multiple isoforms of SUSD3 are known to exist.
Positive Control 1: Cat. No. 1282 - 3T3 (NIH) Cell Lysate
Positive Control 2: Cat. No. 17-201 - 3T3/BALB Cell Slide
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: Predicted: 16, 22, 23, 28 kDa
Observed: 23 kDa
Validation: N/A
Isoform: N/A
Purification: SUSD3 Antibody is affinity chromatography purified via peptide column.
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: SUSD3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Condition: SUSD3 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
Alternate Name: Sushi domain containing 3
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: Little is known of the function of the sushi domain containing 3 protein (SUSD3) , but its expression has been reported in estrogen receptor-alpha (ERalpha) -positive breast tumors with decreased expression reported in aggressive malignant tumors (1, 2) . Recently, SUSD3 has been found to promote estrogen-dependent cell proliferation and may regulate cell-cell and cell-substrate interactions and migration in breast cancer (3) . Furthermore, elevated SUSD3 mRNA levels were observed in aromatase inhibitor-responsive breast tumors, suggesting that it may also serve as a novel predictor of response to endocrine therapy and a potential therapeutic target (3) .